阿齐思罗米和其他宏类的非抗菌作用对支气管上皮屏障和细胞分化
Arni Asbjarnarson1, Jon Petur Joelsson1, Fridrik R Gardarsson2
1School of Health Sciences, University of Iceland, 101 Reykjavík, Iceland.
International journal of molecular sciences
|March 13, 2025
概括
宏类抗生素,如阿齐思罗米,可以增强呼吸上皮质屏障的功能. 这可能解释了它们在减少慢性阻塞性肺病 (COPD) 恶化中的用途.
科学领域:
- 呼吸系统药物 呼吸系统药物
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 呼吸道上皮对于防御吸入的病原体至关重要.
- 表皮屏障功能障碍与COPD等呼吸道疾病有关.
- 麦克罗利德,包括阿齐思罗米 (AZM),用于减少COPD恶化的非标签,可能通过抗炎作用.
研究的目的:
- 为了比较各种宏化物对支气管上皮细胞分化和屏障完整性的影响.
- 调查阿齐思罗米潜在增强上皮屏障功能的基础机制.
主要方法:
- VA10支气管上皮细胞被治疗了14天和21天的红红素,清红素,红素,AZM,沙红素和托布拉米.
- 分析包括RNA测序,体电阻 (TEER) 测定和免疫染色.
- 评估了对表皮分化,屏障完整性和细胞过程的影响.
主要成果:
- 所有测试的宏化物都改变了与表皮细胞转移到介质细胞转移,新陈代谢和免疫调节相关的途径中的基因表达.
- 阿齐思罗米,克拉里思罗米和红色素增加了TEER,并促进了脂的保留.
- 阿齐思罗米独特地增强了上皮屏障,保留了脂,增加了囊泡积累,并影响了角质细胞分化基因组.
结论:
- 麦克罗利德调节支气管上皮细胞中的基因表达.
- 艾兹米,克拉里素和红素改善了上皮膜屏障的完整性和脂的保留.
- 阿齐思罗米对上皮质屏障增强和分化途径表现出明显的影响,这表明其在呼吸系统条件中的益处具有特定的机制.
更多相关视频
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
213
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
213
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
206
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
206
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists
208
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
208
Antiasthma Drugs: Methylxanthines
159
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
159
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K


